Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Qt Group Plc: Share subscriptions based on stock options 2016

Qt Group Plc, Stock exchange release, 16 May 2022, 12:00 noon EESTBetween 5 February and 6 May 2022, a total of 85,010 Qt Group Plc’s new shares has been subscribed for with the company's stock options 2016. For subscriptions made with the stock options 2016, the entire subscription price of EUR 411,448.40 will be entered in the reserve for invested unrestricted equity. After the trade registration the total amount of shares is 25,266,208. The shares subscribed for under the stock options 2016 have been registered in the Trade Register on 16 May 2022, as of which date the new shares

Flexion Mobile bjuder in till företagspresentation och efterföljande frågestund

I samband med mars 2022 kvartalsrapport så bjuder Flexion Mobile in aktieägare, analytiker, media och andra intresserade till en webcast av presentationen. Efteråt så finns det möjlighet att ställa frågor. Presentationen leds av finanschef Niklas Koresaar.   Datum: onsdagen 18 Maj 2022 Tid: 16.00 svensk tid Länk till eventet:  https://www.finwire.tv/webcast/flexion-mobile/q1-presentation-2022/

DanCann Pharma A/S: Establishing a new benchmark in the industry as impressive test results show extreme product purity without the use of radiation

COPENHAGEN, Denmark, 16 May 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce impressive and unique results of analysis for its upcoming products.Tetrahydrocannabinol (“THC”) is one of the active substances extracted from cannabis, and DanCann Pharma has succeeded in extracting biomaterial with a solid content of THC. Now several laboratory tests show that the products are free of contaminants and impurities without the use of radiation - a process that is common within the industry. DanCann Pharma’s

Bulletin from the annual general meeting in Cyxone AB on 16 May 2022

Today, on 16 May 2022, the annual general meeting was held in Cyxone AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Resolution on adoption of accounts and allocation of the company’s result The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual

Pricer showcases color ESLs, consumer engagement, sustainability and shelf availability advances at EuroCIS

At EuroCIS, the most important trade fair for retail technology in Europe, Pricer will be showcasing its scalable solution for in-store communication, together with several ecosystem partners.Pricer, the leading in-store communication company and market leader in electronic shelf labels (ESLs), is proud to be present at EuroCIS in Düsseldorf on May 31 – June 2. Pricer will be showcasing an array of different solutions for in-store efficiency and enhanced customer experience: Pricer SmartTag Color - Pricer will present its extended SmartTag Color range of 4-color ESLs that are using E Ink

BioStock: CombiGene’s new project manager on a broadened pipeline

In parallel with CombiGene’s continued development of drug candidate CG01 together with Spark Therapeutics, the company is investigating the terrain to in-license additional promising gene therapy projects. BioStock spoke to Alvar Grönberg who, after a long career in industry, clinic and academia, recently joined CombiGene as Senior Project Manager, where he plays a crucial role in the company’s upcoming projects.Read the full interview with Alvar Grönberg at biostock.se: https://www.biostock.se/en/2022/05/combigenes-new-project-manager-on-a-broadened-pipeline/ This is a press release

Better customer understanding through service design – Ambassador programme gives Kiiltonians new tools

Last autumn, a total of 40 Kiiltonians attended the Ambassador programme, which helps participants improve their customer experience and service design expertise. With this programme, Kiilto aimed to strengthen and expand its existing knowledge of customer-oriented operating models and service development. The participants found that the programme was a thoroughly positive experience. A new Ambassador programme was launched this spring.The first Ambassador programme brought together Kiiltonians from the company’s construction and industrial adhesives & fireproofing businesses across nine

Resolutions of Nitro Games Oyj’s Annual General Meeting and Board of Directors.

The Annual General Meeting of Nitro Games Oyj (the ”Company”) was held on 16 May 2022 in Kotka, Finland. A total of 12 shareholders and 7,073,804 shares and votes were represented in the meeting.The Annual General Meeting resolved on the following issues: Adoption of the annual accounts, resolution on the measures regarding loss shown on the balance sheet, resolution on the discharge from liability The Annual General Meeting adopted the annual accounts for 2021 and resolved that the net loss of EUR -2,889,531.87 be transferred to the retained earnings / loss account and that no

BioStock: Promore Pharma aims to accelerate healing of venous leg ulcers

Peptide company Promore Pharma is undeniably in an exciting phase with two drug candidates in the field of wound treatment currently in late clinical development, ensereptide and ropocamptide. BioStock has previously taken a closer look at ensereptide, which is now undergoing a phase IIa study, and today we are placing the spotlight on ropocamptide, which is being prepared for a coming phase III study. We took the opportunity to ask CEO Jonas Ekblom a few questions to find out more.Read the whole interview with Promore Pharma's CEO Jonas Ekblom at biostock.se :

INVISIO launching the most versatile headset for both in-vehicle and on-foot missions

Racal Acoustics and INVISIO launch their first joint product solution for the military – the RA5100 Tactical Communication Headset - which combines the technical expertise and operational knowledge of both companies to give users the optimal hearing protection and communication solution for hybrid missions, protecting troops from the most extreme continuous and impulse noise exposure, whether in a vehicle or on foot.  With over 100 years of military hearing protection expertise, Racal Acoustics has designed market leading hearing protection solutions, using its core digital technology

Cardo Health appoints new Head of Product to accelerate growth journey

Stockholm (Sweden), 16 May 2022 Johan Persson, an experienced industry professional and early-stage employee at a digital health-tech company, is joining Cardo Health as their Head of Product. With his 5 years of experience as a medical doctor and over 4 years of experience in digital health, Johan brings invaluable experience to Cardo Health and their journey to democratize access to healthcare.Johan Persson was one of the early-stage employees at digital health-tech company, where he played a key role in product development and international expansion in his roles as Head of Expansion

Linxon wins orders for two turnkey substations in Stockholm, Sweden, that will strengthen the region’s electricity grid

The orders, worth around $12 million, are part of a major investment to upgrade the regional network in Stockholm.Linxon has been awarded orders by Vattenfall Eldistribution to provide two turnkey substations, which will replace old equipment in Gullarängen and Nynäshamn. This modernization is part of Vattenfall's large-scale "Capacity Stockholm" program, a major investment with the aim of strengthening the electricity grid and upgrading the regional network around the capital of Sweden. "We are proud to have been awarded these two projects by Vattenfall Eldistribution, one of our most

SimCorp A/S – Share buyback program

Company Announcement no. 21/2022On February 15, 2022 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR. In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 20.0m, to be executed during the period from February 15, 2022 to July 31, 2022. The following transactions have been executed under the program:          Date                 Number of shares

Invitation – Live presentation of Enad Global 7 AB (publ) report for the first quarter of 2022

EG7 wants to invite its shareholders and other interested parties to a live presentation with Q&A at 9:00am CET on May 25, 2022. The presentation will be led by EG7's acting CEO Ji Ham as well as deputy CEO and CFO Fredrik Rüdén. Questions may be submitted in advance or during the live session to: ir@enadglobal7.com. To access the live presentation with Q&A, please use the following link at the given time: https://tv.streamfabriken.com/eg7-q1-2022

BioStock: Evaxion Biotech shows strong clinical momentum in Q1

Q1 was a productive quarter for Danish immunotherapy company Evaxion Biotech, especially regarding the company’s clinical development.. Lead candidate EVX-01 received regulatory clearance in Australia for phase IIb initiation in melanoma patients, and patient recruitment was completed for the phase I/IIa clinical trial with EVX-02 in resectable melanoma. To cap the quarter off, Evaxion reported a strong cash position of 31.4 MUSD.Read the full article at biostock.se: https://www.biostock.se/en/2022/05/evaxion-biotech-shows-strong-clinical-momentum-in-q1/This is a press release from

Irisity delivers video analytics for Mobotix.

Irisity AB (publ) delivers advanced video analytics for Mobotix in Germany, with an estimated initial order value of EUR 175,000.The contract includes licenses for IRIS Intrution embedded on the Mobotix S7 series.  Due to the confidential nature of the security assets and relationship with the customer, we are unable to disclose any further details regarding this project. For further information: Anna Forsberg, Irisity IR Phone: +46 725 04 69 17 E-mail: anna.forsberg@irisity.com

Oriola and Euroapotheca announce prospective CEO and Chairman of the Board for the planned pharmacy joint venture in Sweden

Press release 16 May 2022 Oriola and Euroapotheca announce prospective CEO and Chairman of the Board for the planned pharmacy joint venture in Sweden As announced on 9 February, Oriola and Euroapotheca have signed a framework merger agreement for combining the respective pharmacy businesses Kronans Apotek and Apoteksgruppen into a new company in Sweden. Now the companies have indicatively agreed that current CEO of Apoteksgruppen Mr. Erik Sjögren will be the prospective CEO of the new company. Additionally, the parties have indicatively agreed that Oriola’s Chairman of the Board Mr.

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release May 16, 2022 at 10:00 a.m. Nokian Tyres has received an announcement from JPMorgan Chase & Co. on May 13, 2022, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the indirect holding in Nokian Tyres shares owned by the funds and accounts managed by JPMorgan Chase & Co. exceeded the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on May 12, 2022. The indirect shareholding of the funds and accounts managed by JPMorgan Chase & Co. in Nokian

Findity raises SEK 50 million to accelerate its international expansion.

The fintech company, Findity, is raising SEK 50 million to accelerate its international expansion and complete a comprehensive company rebrand. The company's two brands, Companyexpense and Findity, come together under one roof, allowing full focus on continued innovation and expansion.The Swedish expense management provider Findity raises SEK 50 million from private investors such as Johan Blomquist, former partner at Altor, Niklas de Bésche, former CEO of Meltwater, as well as existing owners and staff. The company will use the investment to accelerate its international expansion and

Wyld Networks receives initial purchase order from IMAE for Wyld Connect satellite IoT modules

IMAE has placed its initial purchase order, worth SEK 300,000, with Wyld for delivery of Wyld Connect IoT modules. Wyld Networks formed a partnership in early May 2022 with IMAE to deploy its Wyld IoT sensor-to-satellite technology with IMAE’s wind turbine technology in the utility sector in Brazil. Wyld Connect will enable data collection and control for all wind turbines in locations where there is no terrestrial connectivity.“We are delighted to support IMAE in providing satellite IoT connectivity for their next generation wind turbine technology” said Alastair Williamson CEO Wyld

STENOCARE delivers first product batch to the Danish market

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO Today, Monday May 16, 2022, STENOCARE delivers the first product batch of their THC Oil to the Danish market. This means that the product is once again visible in medicinpriser.dk and that all Danish pharmacies can sell the products starting today.STENOCARE has been working intensely with its Canadian partner, AgMEDICA Bioscience, and with The Danish Medicines Agency to have the new medical cannabis oil product accepted into the Danish Pilot Programme for medical cannabis. The license to sell was received in January

Clean Industry Solutions Holding Europe AB presents new website

Evolving and improving to better cater to its supporters’ needs, Clean Industry Solutions Holding Europe AB (CISH) renewed its website design and reintroduces the website now also in Swedish and German. The redesign and language expansion will support CISH’s increasing communication efforts.With the addition of the Swedish and German content, CISH aims to present a more inclusive and accessible website as a channel of communication. The redesigned website also makes it easier for Swedish and German investors to access the CISH shares. The new website is designed for straightforward

Cereno Scientific to present CS014’s preclinical data at top European cardiology congress ESC Congress 2022

Cereno Scientific (XSAT: CRNO B) today announced that an abstract on preclinical drug candidate CS014 has been accepted at the ESC Congress 2022 hosted by the European Society of Cardiology in Barcelona, Spain, on August 26-29. The abstract has been selected for an oral moderated poster presentation and is titled “CS014 is a novel HDAC inhibitor regulating platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding.” It will be presented by Dr. Michael Holinstat, lead of Cereno’s preclinical development programs at University of Michigan

There are no items matching the current filter
There are no more items matching the current filter
Back to top